Immunovant, Inc. (IMVT)
32.11
-1.14
(-3.43%)
USD |
NASDAQ |
Oct 06, 16:00
32.12
+0.01
(+0.03%)
Pre-Market: 09:09
Immunovant Total Liabilities (Quarterly) : 117.10M for June 30, 2026
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 117.10M |
| March 31, 2026 | 104.98M |
| December 31, 2025 | 66.26M |
| September 30, 2025 | 63.25M |
| June 30, 2025 | 52.90M |
| March 31, 2025 | 69.87M |
| December 31, 2024 | 68.32M |
| September 30, 2024 | 66.65M |
| June 30, 2024 | 45.02M |
| March 31, 2024 | 48.96M |
| December 31, 2023 | 32.10M |
| September 30, 2023 | 40.26M |
| June 30, 2023 | 51.36M |
| March 31, 2023 | 43.34M |
| Date | Value |
|---|---|
| December 31, 2022 | 41.56M |
| September 30, 2022 | 32.40M |
| June 30, 2022 | 22.16M |
| March 31, 2022 | 45.74M |
| December 31, 2021 | 38.03M |
| September 30, 2021 | 30.34M |
| June 30, 2021 | 22.50M |
| March 31, 2021 | 21.01M |
| December 31, 2020 | 18.88M |
| September 30, 2020 | 15.49M |
| June 30, 2020 | 22.52M |
| March 31, 2020 | 15.32M |
| December 31, 2019 | 14.76M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Roivant Sciences Ltd. | 384.62M |
| Moderna, Inc. | 4.20B |
| Altimmune, Inc. | 53.00M |
| Vertex Pharmaceuticals, Inc. | 7.175B |
| First Tracks Biotherapeutics, Inc. | 14.34M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 852.49M |
| Shareholders Equity (Quarterly) | 735.39M |
| Current Ratio | 7.269 |
| Net Debt Paydown Yield | 0.00% |